大肿瘤采用更高剂量SBRT治疗I期非小细胞肺癌的第二项研究结果
中位随访44个月,5年总生存率65%、无进展生存率55%、局部复发累积发生率15%,≥2级放射性肺炎累积发生率25%。结论认为新方案局部控制和生存合理、毒性可接受,但提高总剂量并未带来结局改善。
要点
- 按肿瘤长径<1.5 cm、1.5-3 cm、>3 cm分别给予48、50、52 Gy,4次分割。
- 5年OS 65%、PFS 55%、局部复发累积发生率15%,≥2级放射性肺炎25%。
- 提高总剂量未带来结局改善,IA与IB期各终点差异均无统计学意义。
核心结论
- 新SBRT方案局部控制和总生存合理、毒性可接受,但提高总剂量未改善结局。
研究设计与样本
- 按肿瘤最长径分层给予等中心剂量48 Gy(<1.5 cm)、50 Gy(1.5-3 cm)、52 Gy(>3 cm),4次分割、每周2次。
- 采用6 MV光子、4个非共面野和3个共面野实施SBRT。
主要发现
- 全组中位随访44个月,存活患者中位随访61个月。
- 5年总生存率65%、无进展生存率55%、局部复发累积发生率15%。
- 5年OS在57例IA期与14例IB期分别为69%与53%(p=0.44),5年PFS分别为55%与54%(p=0.98)。
- 5年局部复发累积发生率在IA期与IB期分别为11%与31%(p=0.09)。
- ≥2级放射性肺炎累积发生率为25%。
关键数值与推荐
- 处方等中心剂量:肿瘤最长径<1.5 cm为48 Gy,1.5-3 cm为50 Gy,>3 cm为52 Gy,均4次分割。
- 建议至少90%等中心剂量覆盖95% PTV;除1例外,所有病例95% PTV接受至少80%处方剂量。
临床怎么用
- 对I期非小细胞肺癌可按肿瘤大小选择48-52 Gy分4次SBRT,局部控制和毒性可接受。
- 对大肿瘤单纯提高总剂量至52 Gy并未显著改善局部控制或生存,需探索其他增量策略。
局限性
- 研究为回顾性注册(UMIN000027231),非随机对照设计。
- 样本量较小(71例),IA期与IB期亚组分析统计效能有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Efficacy of stereotactic body radiotherapy (SBRT) in stage I non-small-cell lung cancer (NSCLC) has almost been established. In Japan, the protocol of 48 Gy in 4 fractions over 4 days has been most often employed, but higher doses may be necessary to control large tumors. Previously, we conducted a clinical study using SBRT for stage I NSCLC employing different doses depending on tumor diameter, which was closed in 2008. Thereafter, a new study employing higher doses has been conducted, which is reported here. The purpose of this study was to review the safety and effectiveness of the higher doses. METHODS: We escalated the total dose for the improvement of local control for large tumors. In this study, 71 patients underwent SBRT between December 2008 and April 2014. Isocenter doses of 48, 50, and 52 Gy were administered for tumors with a longest diameter of < 1.5 cm, 1.5-3 cm, and > 3 cm, respectively. It was recommended to cover 95% of the PTV with at least 90% of the isocenter dose, and in all but one cases, 95% of the PTV received at least 80% of the prescribed dose. Treatments were delivered in 4 fractions, giving 2 fractions per week. SBRT was performed with 6-MV photons using 4 non-coplanar and 3 coplanar beams. RESULTS: The median follow-up period was 44 months for all patients and 61 months for living patients. Overall survival (OS) was 65%, progression-free survival (PFS) was 55%, and cumulative incidence of local recurrence (LR) was 15% at 5 years. The 5-year OS was 69% for 57 stage IA patients and 53% for 14 stage IB patients (p = 0.44). The 5-year PFS was 55 and 54%, respectively (p = 0.98). The 5-year cumulative incidence of LR was 11 and 31%, respectively (p = 0.09). The cumulative incidence of Grade ≥ 2 radiation pneumonitis was 25%. CONCLUSIONS: Our newer SBRT study yielded reasonable local control and overall survival and acceptable toxicity, but escalating the total dose did not lead to improved outcomes. TRIAL REGISTRATION: UMIN000027231 , registered on 3 May 2017. Retrospectively registered.
引用
- Miyakawa A, Shibamoto Y, Baba F, et al. Stereotactic body radiotherapy for stage I non-small-cell lung cancer using higher doses for larger tumors: results of the second study. Radiat Oncol. 2017. PMID: 28893300. doi:10.1186/s13014-017-0888-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。